IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF- BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF- BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.
Human IGFBP6 expressed in High-5 Insect Cells
CAT# CSC-CTK0207-25 (25 μg); CAT# CSC-CTK0207-125 (125 μg)
High-5 Insect Cells
Greater than 95% as determined by SDS-PAGE and RP-HPLC analysis.
Determined by its ability to inhibit IGF-II induced proliferation of human MCF-7 cells. The expected ED50 for this effect is 0.1 – 0.4 μg/ml.
Less than 1 EU/μg.
Sterile-filtered through a 0.2 micron filter. Lyophilized from a protein solution in 10 mM sodium citrate (pH 3.5).
Please centrifuge product briefly before opening vial. The lyophilized protein should be reconstituted in sterile, ultrapure water or aqueous buffers to a concentration of 0.1- 1.0 mg mg/ml. This solution can then be diluted into other aqueous buffers and stored at -20°C for future use.
Storage & Stability
The lyophilized protein, though stable at room temperature for up to 3 weeks, is best stored desiccated at -20°C. Reconstituted protein should be used immediately or stored long-term in undiluted working aliquots at -20°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid repeated freeze-thaw cycles.
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon.